• In recent days, Novavax reported a strong Q2, with revenue and EPS coming in ahead of analyst expectations, while continuing to advance its vaccine portfolio, including newer programs such as a skin cancer vaccine in partnership with Moderna.
• At the same time, options markets and rising short interest have revealed a sharply divided view on Novavax’s outlook, even as its underlying vaccine strategy gains traction.
• Next, we’ll examine how this better‑than‑expected Q2 performance and vaccine progress might influence Novavax’s existing investment narrative and risk profile.

Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Novavax Investment Narrative Recap

To own Novavax, you need to believe its protein based vaccines and Matrix M adjuvant can support a durable, partner driven business even as COVID revenues reset. The latest Q2 beat and progress on the Moderna partnered skin cancer vaccine are encouraging, but they do not materially change the near term focus on respiratory vaccine uptake as the key catalyst, or the biggest risk around reliance on milestones and royalties from partners to support liquidity.

The skin cancer vaccine news is the most relevant recent development here, because it hints at Matrix M’s potential well beyond infectious disease. Positive trial results with Moderna, paired with higher than expected Q2 results, strengthen the case that non COVID programs could eventually diversify revenue sources. That said, they remain early, and the central question for the next year is still whether Novavax’s respiratory and partnered vaccine portfolio can offset pressure on its core COVID franchise.

Yet beneath this progress, there is a growing risk in the surge of short interest and aggressive options positioning that investors should be aware of...

Novavax's narrative projects $348.5 million revenue and $55.9 million earnings by 2028.

Uncover how Novavax's forecasts yield a $13.78 fair value, a 50% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts were assuming revenues could fall to about US$250.1 million by 2029 and still required earnings of around US$47.5 million, which is a far more pessimistic hurdle than the baseline story and sits uncomfortably beside the more optimistic Matrix M licensing upside you just read about, so it is worth looking at how this new trial and Q2 surprise might shift both of those views.

Explore 3 other fair value estimates on Novavax - why the stock might be worth just $13.78!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Novavax research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Novavax research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Novavax's overall financial health at a glance.

Looking For Alternative Opportunities?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• Uncover the next big thing with 23 elite penny stocks that balance risk and reward.
• The future of work is here. Discover the 38 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Invest in the nuclear renaissance through our list of 92 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.